Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

91
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
91
Nursing Interventions II: Selecting and Classifying the Nursing Interventions01:29

Nursing Interventions II: Selecting and Classifying the Nursing Interventions

2.9K
Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
2.9K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

579
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
579
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

284
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
284
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

102
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
102

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis.

BMJ public health·2026
Same author

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same author

A Method for Estimating Resource Use and Costs when Empirical Data Are Unavailable: Expert Elicitation Study Using the Example of Melanoma.

MDM policy & practice·2026
Same author

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
Same author

Author Reply.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

UK National Screening Committee position statement on evidence required for multicancer detection tests.

BMJ (Clinical research ed.)·2026

Related Experiment Video

Updated: Dec 5, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

Implementing Interventions with Varying Marginal Cost-Effectiveness: An Application in Precision Medicine.

Stuart J Wright1, Mike Paulden2, Katherine Payne1

  • 1Manchester Centre for Health Economics, Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, Greater Manchester, UK.

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|October 21, 2020
PubMed
Summary

Implementing precision medicine requires a minimum of 51% adoption to be cost-effective. Poor implementation strategies can negatively impact health systems economically, highlighting the need for improved strategies to ensure cost-effective healthcare.

Keywords:
breast cancereconomic evaluationimplementationprecision medicine

More Related Videos

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

772

Related Experiment Videos

Last Updated: Dec 5, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.6K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

772

Area of Science:

  • Health Economics
  • Precision Medicine Implementation
  • Cost-Effectiveness Analysis

Background:

  • Barriers to precision medicine implementation can affect cost-effectiveness.
  • Marginal costs and consequences of precision medicine vary with implementation levels.
  • Understanding these variations is crucial for assessing the value of implementation strategies.

Purpose of the Study:

  • To illustrate and quantify the impact of varying marginal costs and benefits on precision medicine implementation value.
  • To adapt existing methods for calculating implementation value under varying cost and consequence scenarios.
  • To analyze a case study of a 70-gene recurrence score for breast cancer.

Main Methods:

  • Adapted an existing implementation value calculation method.
  • Incorporated varying marginal costs and consequences across implementation levels.
  • Utilized a case study based on a decision-analytic model for breast cancer recurrence score.

Main Results:

  • A minimum implementation level of 51% is needed for the 70-gene recurrence score to be cost-effective (€20,000/QALY threshold).
  • Net monetary benefit varied based on initial and final implementation levels.
  • Dynamic models showed accumulating losses from low implementation over time.

Conclusions:

  • Suboptimal implementation of cost-effective precision medicine significantly impacts health system economics.
  • Strategies to enhance precision medicine implementation are vital for realizing cost-effective healthcare.
  • Economic evaluation of implementation strategies can optimize healthcare budget utilization.